Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7910608 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months from now) | |
US7585879 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months from now) | |
US7288657 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Dec, 2025
(1 year, 7 months from now) | |
US9765028 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
US11858898 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
US10550081 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
US8541451 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Aug, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10106503 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months from now) | |
US8034946 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months from now) | |
US8053448 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months from now) | |
US10343995 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months from now) | |
US11247969 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months from now) | |
US7521041 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months from now) | |
US8273894 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months from now) | |
US7491736 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months from now) | |
US7550595 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(10 months from now) | |
US11008289 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
US11691948 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(6 years from now) | |
US11484531 | MYLAN IRELAND LTD | Methods for treating chronic obstructive pulmonary disease |
Oct, 2039
(15 years from now) |
Yupelri is owned by Mylan Ireland Ltd.
Yupelri contains Revefenacin.
Yupelri has a total of 19 drug patents out of which 0 drug patents have expired.
Yupelri was authorised for market use on 09 November, 2018.
Yupelri is available in solution;inhalation dosage forms.
Yupelri can be used as for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd).
Drug patent challenges can be filed against Yupelri from 09 November, 2022.
The generics of Yupelri are possible to be released after 23 October, 2039.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 09, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: 09 November, 2022
Market Authorisation Date: 09 November, 2018
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION;INHALATION